{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T02:58:19Z","timestamp":1792724299329,"version":"4.5.0"},"reference-count":141,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2008,9,1]],"date-time":"2008-09-01T00:00:00Z","timestamp":1220227200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Mayo Clinic Proceedings"],"published-print":{"date-parts":[[2008,9]]},"DOI":"10.4065\/83.9.1032","type":"journal-article","created":{"date-parts":[[2009,1,23]],"date-time":"2009-01-23T20:31:26Z","timestamp":1232742686000},"page":"1032-1045","source":"Crossref","is-referenced-by-count":1398,"title":["Bisphosphonates: Mechanism of Action and Role in Clinical Practice"],"prefix":"10.4065","volume":"83","author":[{"given":"Matthew T.","family":"Drake","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bart L.","family":"Clarke","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sundeep","family":"Khosla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.4065\/83.9.1032_bib1","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates: from bench to bedside","volume":"1068","author":"Russell","year":"2006","journal-title":"Ann N Y Acad Sci"},{"issue":"5065","key":"10.4065\/83.9.1032_bib2","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1038\/212901a0","article-title":"Effect of pyrophosphate on hydroxyapatite and its implications in calcium homeostasis","volume":"212","author":"Fleisch","year":"1966","journal-title":"Nature"},{"issue":"3","key":"10.4065\/83.9.1032_bib3","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1007\/BF02196199","article-title":"The influence of pyrophosphate, condensed phosphates, phosphonates and other phosphate compounds on the dissolution of hydroxyapatite in vitro and on bone resorption induced by parathyroid hormone in tissue culture and in thyroparathyroidectomised rats","volume":"6","author":"Russell","year":"1970","journal-title":"Calcif Tissue Res"},{"issue":"10","key":"10.4065\/83.9.1032_bib4","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1172\/JCI6800","article-title":"Prevention of osteocyte and osteoblast apoptosis by bisphosphonates and calcitonin","volume":"104","author":"Plotkin","year":"1999","journal-title":"J Clin Invest"},{"key":"10.4065\/83.9.1032_bib5","doi-asserted-by":"crossref","first-page":"7317","DOI":"10.1074\/jbc.M412817200","article-title":"Bisphosphonates and estrogens inhibit osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular signal-regulated kinase activation","volume":"280","author":"Plotkin","year":"2005","journal-title":"J Biol Chem"},{"issue":"2","key":"10.4065\/83.9.1032_bib6","doi-asserted-by":"crossref","first-page":"235","DOI":"10.1016\/S0022-3565(24)38786-5","article-title":"Structure-activity relationships for inhibition of farnesyl diphosphate synthase in vitro and inhibition of bone resorption in vivo by nitrogen-containing bisphosphonates","volume":"296","author":"Dunford","year":"2001","journal-title":"J Pharmacol Exp Ther"},{"issue":"20","key":"10.4065\/83.9.1032_bib7","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.0601643103","article-title":"The molecular mechanism of nitrogen-containing bisphosphonates as antiosteoporosis drugs","volume":"103","author":"Kavanagh","year":"2006","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"5350","key":"10.4065\/83.9.1032_bib8","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1126\/science.279.5350.509","article-title":"Rho GTPases and the actin cytoskeleton","volume":"279","author":"Hall","year":"1998","journal-title":"Science"},{"issue":"4","key":"10.4065\/83.9.1032_bib9","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1359\/jbmr.1998.13.4.581","article-title":"Nitrogen-containing bisphosphonates inhibit the mevalonate pathway and prevent post-translational prenylation of GTP-binding proteins, including Ras","volume":"13","author":"Luckman","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.4065\/83.9.1032_bib10","doi-asserted-by":"crossref","first-page":"1988","DOI":"10.1359\/jbmr.2002.17.11.1988","article-title":"Two-year results of once-weekly administration of alendronate 70 mg for the treatment of postmenopausal osteoporosis","volume":"17","author":"Rizzoli","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.4065\/83.9.1032_bib11","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1007\/s00223-002-2011-8","article-title":"The efficacy and tolerability of risedronate once a week for the treatment of postmenopausal osteoporosis","volume":"71","author":"Brown","year":"2002","journal-title":"Calcif Tissue Int"},{"issue":"6","key":"10.4065\/83.9.1032_bib12","doi-asserted-by":"crossref","first-page":"551","DOI":"10.2165\/00003088-200544060-00001","article-title":"Pharmacokinetics\/pharmacodynamics of bisphosphonates: use for optimisation of intermittent therapy for osteoporosis","volume":"44","author":"Cremers","year":"2005","journal-title":"Clin Pharmacokinet"},{"issue":"9","key":"10.4065\/83.9.1032_bib13","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"issue":"18","key":"10.4065\/83.9.1032_bib14","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.4065\/83.9.1032_bib15","doi-asserted-by":"crossref","first-page":"1700","DOI":"10.1359\/jbmr.1997.12.10.1700","article-title":"Elimination and biochemical responses to intravenous alendronate in postmenopausal osteoporosis","volume":"12","author":"Khan","year":"1997","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.4065\/83.9.1032_bib16","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/8756-3282(95)00445-9","article-title":"Bisphosphonates: a review of their pharmacokinetic properties","volume":"18","author":"Lin","year":"1996","journal-title":"Bone"},{"issue":"2","key":"10.4065\/83.9.1032_bib17","doi-asserted-by":"crossref","first-page":"236","DOI":"10.1016\/j.clinthera.2006.01.002","article-title":"Determinants of persistence with bisphosphonates: a study in women with postmenopausal osteoporosis","volume":"28","author":"Penning-van Beest","year":"2006","journal-title":"Clin Ther"},{"issue":"6","key":"10.4065\/83.9.1032_bib18","doi-asserted-by":"crossref","first-page":"914","DOI":"10.1007\/s00198-006-0073-6","article-title":"Determinants of adherence to osteoporosis treatment in clinical practice","volume":"17","author":"Rossini","year":"2006","journal-title":"Osteoporos Int"},{"issue":"12","key":"10.4065\/83.9.1032_bib19","doi-asserted-by":"crossref","first-page":"965","DOI":"10.1007\/s00198-003-1502-4","article-title":"Compliance with pharmacologic therapy for osteoporosis","volume":"14","author":"Yood","year":"2003","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.4065\/83.9.1032_bib20","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"11","key":"10.4065\/83.9.1032_bib21","doi-asserted-by":"crossref","first-page":"1638","DOI":"10.1007\/s00198-006-0166-2","article-title":"Factors associated with adherence and persistence to bisphosphonate therapy in osteoporosis: a cross-sectional survey","volume":"17","author":"Carr","year":"2006","journal-title":"Osteoporos Int"},{"issue":"5","key":"10.4065\/83.9.1032_bib22","doi-asserted-by":"crossref","first-page":"687","DOI":"10.1016\/S8756-3282(00)00376-8","article-title":"Alendronate increases bone strength by increasing the mean degree of mineralization of bone tissue in osteoporotic women","volume":"27","author":"Boivin","year":"2000","journal-title":"Bone"},{"issue":"3","key":"10.4065\/83.9.1032_bib23","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results From the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"issue":"9041","key":"10.4065\/83.9.1032_bib24","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"issue":"24","key":"10.4065\/83.9.1032_bib25","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"issue":"14","key":"10.4065\/83.9.1032_bib26","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"issue":"5","key":"10.4065\/83.9.1032_bib27","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"issue":"22","key":"10.4065\/83.9.1032_bib28","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1056\/NEJM199511303332201","article-title":"Effect of oral alendronate on bone mineral density and the incidence of fractures in postmenopausal osteoporosis","volume":"333","author":"Liberman","year":"1995","journal-title":"N Engl J Med"},{"issue":"10","key":"10.4065\/83.9.1032_bib29","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"issue":"8","key":"10.4065\/83.9.1032_bib30","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"1","key":"10.4065\/83.9.1032_bib31","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1359\/jbmr.2002.17.1.11","article-title":"Bone turnover matters: the raloxifene treatment paradox of dramatic decreases in vertebral fractures without commensurate increases in bone density [editorial]","volume":"17","author":"Riggs","year":"2002","journal-title":"J Bone Miner Res"},{"issue":"12","key":"10.4065\/83.9.1032_bib32","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1056\/NEJMoa030897","article-title":"Ten years' experience with alendronate for osteoporosis in postmenopausal women","volume":"350","author":"Bone","year":"2004","journal-title":"N Engl J Med"},{"issue":"9","key":"10.4065\/83.9.1032_bib33","doi-asserted-by":"crossref","first-page":"604","DOI":"10.1056\/NEJM200008313430902","article-title":"Alendronate for the treatment of osteoporosis in men","volume":"343","author":"Orwoll","year":"2000","journal-title":"N Engl J Med"},{"issue":"8","key":"10.4065\/83.9.1032_bib34","doi-asserted-by":"crossref","first-page":"2882","DOI":"10.1210\/jc.2006-0190","article-title":"Effects of teriparatide, alendronate, or both on bone turnover in osteoporotic men","volume":"91","author":"Finkelstein","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"12","key":"10.4065\/83.9.1032_bib35","doi-asserted-by":"crossref","first-page":"992","DOI":"10.1007\/s00198-004-1636-z","article-title":"The importance of bisphosphonate therapy in maintaining bone mass in men after therapy with teriparatide [human parathyroid hormone(1-34)]","volume":"15","author":"Kurland","year":"2004","journal-title":"Osteoporos Int"},{"issue":"24","key":"10.4065\/83.9.1032_bib36","doi-asserted-by":"crossref","first-page":"2927","DOI":"10.1001\/jama.296.24.2927","article-title":"Effects of continuing or stopping alendronate after 5 years of treatment: the Fracture Intervention Trial Long-term Extension (FLEX): a randomized trial","volume":"296","author":"Black","year":"2006","journal-title":"JAMA"},{"issue":"1","key":"10.4065\/83.9.1032_bib37","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1016\/j.bone.2007.09.001","article-title":"Efficacy and safety of risedronate 150 mg once a month in the treatment of postmenopausal osteoporosis","volume":"42","author":"Delmas","year":"2008","journal-title":"Bone"},{"issue":"18","key":"10.4065\/83.9.1032_bib38","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"issue":"1","key":"10.4065\/83.9.1032_bib39","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1016\/j.bone.2007.03.011","article-title":"Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate","volume":"41","author":"McClung","year":"2007","journal-title":"Bone"},{"issue":"11","key":"10.4065\/83.9.1032_bib40","doi-asserted-by":"crossref","first-page":"875","DOI":"10.7326\/0003-4819-137-11-200212030-00008","article-title":"Significant differential effects of alendronate, estrogen, or combination therapy on the rate of bone loss after discontinuation of treatment of postmenopausal osteoporosis: a randomized, double-blind, placebo-controlled trial","volume":"137","author":"Greenspan","year":"2002","journal-title":"Ann Intern Med"},{"issue":"5","key":"10.4065\/83.9.1032_bib41","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1046\/j.1365-2265.2002.01536.x","article-title":"Combination therapy for postmenopausal osteoporosis","volume":"56","author":"Compston","year":"2002","journal-title":"Clin Endocrinol (Oxf)"},{"issue":"24","key":"10.4065\/83.9.1032_bib42","doi-asserted-by":"crossref","first-page":"1618","DOI":"10.1056\/NEJM199412153312404","article-title":"Parathyroid hormone for the prevention of bone loss induced by estrogen deficiency","volume":"331","author":"Finkelstein","year":"1994","journal-title":"N Engl J Med"},{"issue":"19","key":"10.4065\/83.9.1032_bib43","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"issue":"6","key":"10.4065\/83.9.1032_bib44","doi-asserted-by":"crossref","first-page":"566","DOI":"10.1056\/NEJMoa050157","article-title":"Daily and cyclic parathyroid hormone in women receiving alendronate","volume":"353","author":"Cosman","year":"2005","journal-title":"N Engl J Med"},{"issue":"13","key":"10.4065\/83.9.1032_bib45","doi-asserted-by":"crossref","first-page":"1207","DOI":"10.1056\/NEJMoa031975","article-title":"The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis","volume":"349","author":"Black","year":"2003","journal-title":"N Engl J Med"},{"issue":"13","key":"10.4065\/83.9.1032_bib46","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa035725","article-title":"The effects of parathyroid hormone, alendronate, or both in men with osteoporosis","volume":"349","author":"Finkelstein","year":"2003","journal-title":"N Engl J Med"},{"issue":"6","key":"10.4065\/83.9.1032_bib47","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1210\/jc.85.6.2129","article-title":"Enhancement of bone mass in osteoporotic women with parathyroid hormone followed by alendronate","volume":"85","author":"Rittmaster","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.4065\/83.9.1032_bib48","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1056\/NEJMoa050336","article-title":"One year of alendronate after one year of parathyroid hormone (1-84) for osteoporosis","volume":"353","author":"Black","year":"2005","journal-title":"N Engl J Med"},{"issue":"6","key":"10.4065\/83.9.1032_bib49","doi-asserted-by":"crossref","first-page":"591","DOI":"10.1001\/archinte.167.6.591","article-title":"Challenges in improving the quality of osteoporosis care for long-term glucocorticoid users: a prospective randomized trial","volume":"167","author":"Curtis","year":"2007","journal-title":"Arch Intern Med"},{"issue":"7","key":"10.4065\/83.9.1032_bib50","doi-asserted-by":"crossref","first-page":"675","DOI":"10.1056\/NEJMoa053569","article-title":"Alendronate or alfacalcidol in glucocorticoid-induced osteoporosis","volume":"355","author":"de Nijs","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.4065\/83.9.1032_bib51","doi-asserted-by":"crossref","first-page":"460","DOI":"10.1093\/rheumatology\/kel249","article-title":"Individual fracture risk and the cost-effectiveness of bisphosphonates in patients using oral glucocorticoids","volume":"46","author":"van Staa","year":"2007","journal-title":"Rheumatology (Oxford)"},{"issue":"4","key":"10.4065\/83.9.1032_bib52","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1007\/s002239900334","article-title":"Primary prevention of glucocorticoid-induced osteoporosis with intermittent intravenous pamidronate: a randomized trial","volume":"61","author":"Boutsen","year":"1997","journal-title":"Calcif Tissue Int"},{"issue":"10","key":"10.4065\/83.9.1032_bib53","doi-asserted-by":"crossref","first-page":"801","DOI":"10.1007\/s00198-003-1425-0","article-title":"Intermittent intravenous ibandronate injections reduce vertebral fracture risk in corticosteroid-induced osteoporosis: results from a long-term comparative study","volume":"14","author":"Ringe","year":"2003","journal-title":"Osteoporos Int"},{"issue":"2","key":"10.4065\/83.9.1032_bib54","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1007\/s001980170142","article-title":"Intravenous pamidronate as treatment for osteoporosis after heart transplantation: a prospective study","volume":"12","author":"Krieg","year":"2001","journal-title":"Osteoporos Int"},{"issue":"10","key":"10.4065\/83.9.1032_bib55","doi-asserted-by":"crossref","first-page":"2669","DOI":"10.1097\/01.ASN.0000087092.53894.80","article-title":"Prevention of bone loss in renal transplant recipients: a prospective, randomized trial of intravenous pamidronate","volume":"14","author":"Coco","year":"2003","journal-title":"J Am Soc Nephrol"},{"issue":"3 pt 1","key":"10.4065\/83.9.1032_bib56","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1164\/ajrccm.162.3.2002051","article-title":"Efficacy of pamidronate for osteoporosis in patients with cystic fibrosis following lung transplantation","volume":"162","author":"Aris","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.4065\/83.9.1032_bib57","doi-asserted-by":"crossref","first-page":"1530","DOI":"10.1681\/ASN.V1271530","article-title":"Effect of ibandronate on bone loss and renal function after kidney transplantation","volume":"12","author":"Grotz","year":"2001","journal-title":"J Am Soc Nephrol"},{"issue":"11","key":"10.4065\/83.9.1032_bib58","doi-asserted-by":"crossref","first-page":"2111","DOI":"10.1359\/jbmr.2001.16.11.2111","article-title":"Alendronate prevents further bone loss in renal transplant recipients","volume":"16","author":"Giannini","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.4065\/83.9.1032_bib59","doi-asserted-by":"crossref","first-page":"627","DOI":"10.1210\/jc.2004-0509","article-title":"Short-term zoledronic acid treatment increases bone mineral density and marrow clonogenic fibroblast progenitors after allogeneic stem cell transplantation","volume":"90","author":"Tauchmanova","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"10","key":"10.4065\/83.9.1032_bib60","doi-asserted-by":"crossref","first-page":"3835","DOI":"10.1210\/jc.2006-0684","article-title":"Pamidronate reduces bone loss after allogeneic stem cell transplantation","volume":"91","author":"Grigg","year":"2006","journal-title":"J Clin Endocrinol Metab"},{"issue":"9","key":"10.4065\/83.9.1032_bib61","doi-asserted-by":"crossref","first-page":"600","DOI":"10.1111\/j.1445-5994.2006.01154.x","article-title":"Zoledronic acid prevents bone loss after allogeneic haemopoietic stem cell transplantation","volume":"36","author":"D'Souza","year":"2006","journal-title":"Intern Med J"},{"issue":"4","key":"10.4065\/83.9.1032_bib62","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1038\/sj.bmt.1705918","article-title":"High prevalence of early-onset osteopenia\/osteoporosis after allogeneic stem cell transplantation and improvement after bisphosphonate therapy","volume":"41","author":"Yao","year":"2008","journal-title":"Bone Marrow Transplant"},{"issue":"20","key":"10.4065\/83.9.1032_bib63","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1056\/NEJMoa071408","article-title":"Teriparatide or alendronate in glucocorticoid-induced osteoporosis","volume":"357","author":"Saag","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.4065\/83.9.1032_bib64","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1210\/jc.2006-2013","article-title":"Alendronate prevents bone loss in patients with acute spinal cord injury: a randomized, double-blind, placebo-controlled study","volume":"92","author":"Gilchrist","year":"2007","journal-title":"J Clin Endocrinol Metab"},{"issue":"3","key":"10.4065\/83.9.1032_bib65","doi-asserted-by":"crossref","first-page":"243","DOI":"10.1016\/S0003-9993(99)90133-8","article-title":"Intravenous pamidronate attenuates bone density loss after acute spinal cord injury","volume":"80","author":"Nance","year":"1999","journal-title":"Arch Phys Med Rehabil"},{"issue":"11","key":"10.4065\/83.9.1032_bib66","doi-asserted-by":"crossref","first-page":"2126","DOI":"10.1359\/jbmr.2001.16.11.2126","article-title":"Alendronate reduces periprosthetic bone loss after uncemented primary total hip arthroplasty: a prospective randomized study","volume":"16","author":"Venesmaa","year":"2001","journal-title":"J Bone Miner Res"},{"issue":"7","key":"10.4065\/83.9.1032_bib67","doi-asserted-by":"crossref","first-page":"1009","DOI":"10.1007\/s00198-007-0339-7","article-title":"Risedronate reduces postoperative bone resorption after cementless total hip arthroplasty","volume":"18","author":"Yamasaki","year":"2007","journal-title":"Osteoporos Int"},{"issue":"6","key":"10.4065\/83.9.1032_bib68","doi-asserted-by":"crossref","first-page":"593","DOI":"10.1056\/NEJMcp060278","article-title":"Paget's disease of bone","volume":"355","author":"Whyte","year":"2006","journal-title":"N Engl J Med"},{"issue":"3","key":"10.4065\/83.9.1032_bib69","doi-asserted-by":"crossref","first-page":"961","DOI":"10.1210\/jc.81.3.961","article-title":"Comparative study of alendronate versus etidronate for the treatment of Paget's disease of bone","volume":"81","author":"Siris","year":"1996","journal-title":"J Clin Endocrinol Metab"},{"issue":"6","key":"10.4065\/83.9.1032_bib70","doi-asserted-by":"crossref","first-page":"1032","DOI":"10.1359\/jbmr.1998.13.6.1032","article-title":"Risedronate in the treatment of Paget's disease of bone: an open label, multicenter study","volume":"13","author":"Siris","year":"1998","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.4065\/83.9.1032_bib71","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1002\/jbmr.5650090302","article-title":"Perspectives: a practical guide to the use of pamidronate in the treatment of Paget's disease","volume":"9","author":"Siris","year":"1994","journal-title":"J Bone Miner Res"},{"issue":"9","key":"10.4065\/83.9.1032_bib72","doi-asserted-by":"crossref","first-page":"898","DOI":"10.1056\/NEJMoa044241","article-title":"Comparison of a single infusion of zoledronic acid with risedronate for Paget's disease","volume":"353","author":"Reid","year":"2005","journal-title":"N Engl J Med"},{"key":"10.4065\/83.9.1032_bib73","series-title":"Primer on the Metabolic Diseases and Disorders of Mineral Metabolism","first-page":"383","article-title":"Treatment and prevention of bone metastases and myeloma in bone disease","author":"Body","year":"2006"},{"issue":"24","key":"10.4065\/83.9.1032_bib74","doi-asserted-by":"crossref","first-page":"1785","DOI":"10.1056\/NEJM199612123352401","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases","volume":"335","author":"Hortobagyi","year":"1996","journal-title":"N Engl J Med"},{"issue":"6","key":"10.4065\/83.9.1032_bib75","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1200\/JCO.1998.16.6.2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate","volume":"16","author":"Hortobagyi","year":"1998","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.4065\/83.9.1032_bib76","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1002\/(SICI)1097-0142(20000301)88:5<1082::AID-CNCR20>3.0.CO;2-Z","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton","year":"2000","journal-title":"Cancer"},{"issue":"12","key":"10.4065\/83.9.1032_bib77","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"issue":"30","key":"10.4065\/83.9.1032_bib78","doi-asserted-by":"crossref","first-page":"4895","DOI":"10.1200\/JCO.2006.05.9212","article-title":"Phase II trial evaluating the palliative benefit of second-line zoledronic acid in breast cancer patients with either a skeletal-related event or progressive bone metastases despite first-line bisphosphonate therapy","volume":"24","author":"Clemons","year":"2006","journal-title":"J Clin Oncol"},{"issue":"9","key":"10.4065\/83.9.1032_bib79","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1093\/annonc\/mdg367","article-title":"Intravenous ibandronate reduces the incidence of skeletal complications in patients with breast cancer and bone metastases","volume":"14","author":"Body","year":"2003","journal-title":"Ann Oncol"},{"issue":"3","key":"10.4065\/83.9.1032_bib80","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pain.2004.07.011","article-title":"Oral ibandronate improves bone pain and preserves quality of life in patients with skeletal metastases due to breast cancer","volume":"111","author":"Body","year":"2004","journal-title":"Pain"},{"issue":"6","key":"10.4065\/83.9.1032_bib81","doi-asserted-by":"crossref","first-page":"1133","DOI":"10.1038\/sj.bjc.6601663","article-title":"Oral ibandronate reduces the risk of skeletal complications in breast cancer patients with metastatic bone disease: results from two randomised, placebo-controlled phase III studies","volume":"90","author":"Body","year":"2004","journal-title":"Br J Cancer"},{"issue":"15","key":"10.4065\/83.9.1032_bib82","doi-asserted-by":"crossref","first-page":"3219","DOI":"10.1200\/JCO.2002.11.080","article-title":"Randomized, placebo-controlled trial of clodronate in patients with primary operable breast cancer","volume":"20","author":"Powles","year":"2002","journal-title":"J Clin Oncol"},{"issue":"suppl 1","key":"10.4065\/83.9.1032_bib83","doi-asserted-by":"crossref","first-page":"S30","DOI":"10.3747\/co.2008.174","article-title":"Cancer treatment-related bone loss: a review and synthesis of the literature","volume":"15","author":"Khan","year":"2008","journal-title":"Curr Oncol"},{"issue":"7","key":"10.4065\/83.9.1032_bib84","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1200\/JCO.2005.02.7102","article-title":"Zoledronic acid prevents cancer treatment-induced bone loss in premenopausal women receiving adjuvant endocrine therapy for hormone-responsive breast cancer: a report from the Austrian Breast and Colorectal Cancer Study Group","volume":"25","author":"Gnant","year":"2007","journal-title":"J Clin Oncol"},{"issue":"3","key":"10.4065\/83.9.1032_bib85","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.bone.2007.06.004","article-title":"Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole: prevention with bisphosphonates","volume":"41","author":"Confavreux","year":"2007","journal-title":"Bone"},{"issue":"4","key":"10.4065\/83.9.1032_bib86","doi-asserted-by":"crossref","first-page":"858","DOI":"10.1054\/bjoc.1999.1012","article-title":"Markers of bone turnover for the management of patients with bone metastases from prostate cancer","volume":"82","author":"Garnero","year":"2000","journal-title":"Br J Cancer"},{"issue":"19","key":"10.4065\/83.9.1032_bib87","doi-asserted-by":"crossref","first-page":"1458","DOI":"10.1093\/jnci\/94.19.1458","article-title":"A randomized, placebo-controlled trial of zoledronic acid in patients with hormone-refractory metastatic prostate carcinoma","volume":"94","author":"Saad","year":"2002","journal-title":"J Natl Cancer Inst"},{"issue":"11","key":"10.4065\/83.9.1032_bib88","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"issue":"13","key":"10.4065\/83.9.1032_bib89","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1056\/NEJMoa010845","article-title":"Pamidronate to prevent bone loss during androgen-deprivation therapy for prostate cancer","volume":"345","author":"Smith","year":"2001","journal-title":"N Engl J Med"},{"issue":"9","key":"10.4065\/83.9.1032_bib90","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1200\/JCO.2006.07.3361","article-title":"Randomized controlled trial of annual zoledronic acid to prevent gonadotropin-releasing hormone agonist-induced bone loss in men with prostate cancer","volume":"25","author":"Michaelson","year":"2007","journal-title":"J Clin Oncol"},{"issue":"6","key":"10.4065\/83.9.1032_bib91","doi-asserted-by":"crossref","first-page":"2008","DOI":"10.1097\/01.ju.0000063820.94994.95","article-title":"Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer","volume":"169","author":"Smith","year":"2003","journal-title":"J Urol"},{"issue":"12","key":"10.4065\/83.9.1032_bib92","doi-asserted-by":"crossref","first-page":"1071","DOI":"10.1111\/j.1442-2042.2007.01911.x","article-title":"Preventive effect of risedronate on bone loss in men receiving androgen-deprivation therapy for prostate cancer","volume":"14","author":"Ishizaka","year":"2007","journal-title":"Int J Urol"},{"key":"10.4065\/83.9.1032_bib93","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"issue":"7","key":"10.4065\/83.9.1032_bib94","doi-asserted-by":"crossref","first-page":"1191","DOI":"10.1002\/1097-0142(20010401)91:7<1191::AID-CNCR1119>3.0.CO;2-0","article-title":"Zoledronic acid reduces skeletal-related events in patients with osteolytic metastases","volume":"91","author":"Berenson","year":"2001","journal-title":"Cancer"},{"issue":"5","key":"10.4065\/83.9.1032_bib95","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"issue":"17","key":"10.4065\/83.9.1032_bib96","doi-asserted-by":"crossref","first-page":"3719","DOI":"10.1200\/JCO.2002.06.037","article-title":"American Society of Clinical Oncology clinical practice guidelines: the role of bisphosphonates in multiple myeloma","volume":"20","author":"Berenson","year":"2002","journal-title":"J Clin Oncol"},{"issue":"8","key":"10.4065\/83.9.1032_bib97","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.4065\/81.8.1047","article-title":"Mayo Clinic consensus statement for the use of bisphosphonates in multiple myeloma","volume":"81","author":"Lacy","year":"2006","journal-title":"Mayo Clin Proc"},{"issue":"4","key":"10.4065\/83.9.1032_bib98","doi-asserted-by":"crossref","first-page":"516","DOI":"10.4065\/82.4.516","article-title":"Use of bisphosphonates in multiple myeloma: IMWG response to Mayo Clinic consensus statement [letter]","volume":"82","author":"Durie","year":"2007","journal-title":"Mayo Clin Proc"},{"issue":"5","key":"10.4065\/83.9.1032_bib99","doi-asserted-by":"crossref","first-page":"962","DOI":"10.1002\/cncr.11571","article-title":"Zoledronic acid delays the onset of skeletal-related events and progression of skeletal disease in patients with advanced renal cell carcinoma","volume":"98","author":"Lipton","year":"2003","journal-title":"Cancer"},{"issue":"suppl 2","key":"10.4065\/83.9.1032_bib100","doi-asserted-by":"crossref","first-page":"S163","DOI":"10.1542\/peds.2006-2023I","article-title":"Experience with bisphosphonates in osteogenesis imperfecta","volume":"119","author":"Glorieux","year":"2007","journal-title":"Pediatrics"},{"issue":"9","key":"10.4065\/83.9.1032_bib101","doi-asserted-by":"crossref","first-page":"1293","DOI":"10.1172\/JCI0215952","article-title":"The effects of intravenous pamidronate on the bone tissue of children and adolescents with osteogenesis imperfecta","volume":"110","author":"Rauch","year":"2002","journal-title":"J Clin Invest"},{"issue":"5","key":"10.4065\/83.9.1032_bib102","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1097\/01.bpo.0000164871.36098.4c","article-title":"Efficacy of oral alendronate in children with osteogenesis imperfecta","volume":"25","author":"Cho","year":"2005","journal-title":"J Pediatr Orthop"},{"issue":"1","key":"10.4065\/83.9.1032_bib103","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1359\/JBMR.051006","article-title":"Two-year clinical trial of oral alendronate versus intravenous pamidronate in children with osteogenesis imperfecta","volume":"21","author":"DiMeglio","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"2","key":"10.4065\/83.9.1032_bib104","first-page":"105","article-title":"Alendronate treatment in children with osteogenesis imperfecta","volume":"45","author":"Akcay","year":"2008","journal-title":"Indian Pediatr"},{"issue":"2","key":"10.4065\/83.9.1032_bib105","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1097\/00009957-200303000-00001","article-title":"Modern approach to children with osteogenesis imperfecta","volume":"12","author":"Zeitlin","year":"2003","journal-title":"J Pediatr Orthop B"},{"issue":"7","key":"10.4065\/83.9.1032_bib106","doi-asserted-by":"crossref","first-page":"1235","DOI":"10.1359\/JBMR.050213","article-title":"Effects of intravenous pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome","volume":"20","author":"Munns","year":"2005","journal-title":"J Bone Miner Res"},{"issue":"4","key":"10.4065\/83.9.1032_bib107","doi-asserted-by":"crossref","DOI":"10.1002\/14651858.CD005324.pub2","article-title":"Bisphosphonate therapy for children and adolescents with secondary osteoporosis","author":"Ward","year":"2007","journal-title":"Cochrane Database Syst Rev"},{"issue":"5","key":"10.4065\/83.9.1032_bib108","doi-asserted-by":"crossref","first-page":"513","DOI":"10.4158\/EP.13.5.513","article-title":"Consensus and controversy regarding osteoporosis in the pediatric population","volume":"13","author":"Bachrach","year":"2007","journal-title":"Endocr Pract"},{"issue":"10","key":"10.4065\/83.9.1032_bib109","doi-asserted-by":"crossref","first-page":"1075","DOI":"10.1056\/NEJMc062792","article-title":"Prolonged bisphosphonate release after treatment in children [letter]","volume":"356","author":"Papapoulos","year":"2007","journal-title":"N Engl J Med"},{"issue":"10","key":"10.4065\/83.9.1032_bib110","doi-asserted-by":"crossref","first-page":"1742","DOI":"10.1359\/JBMR.040711","article-title":"Maternal and fetal outcome after long-term pamidronate treatment before conception: a report of two cases","volume":"19","author":"Munns","year":"2004","journal-title":"J Bone Miner Res"},{"issue":"10","key":"10.4065\/83.9.1032_bib111","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"issue":"7","key":"10.4065\/83.9.1032_bib112","first-page":"968","article-title":"Osteonecrosis of the jaw in patients with multiple myeloma treated with bisphosphonates: evidence of increased risk after treatment with zoledronic acid","volume":"91","author":"Dimopoulos","year":"2006","journal-title":"Haematologica"},{"issue":"7","key":"10.4065\/83.9.1032_bib113","doi-asserted-by":"crossref","first-page":"1545","DOI":"10.1038\/sj.leu.2404682","article-title":"A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma","volume":"21","author":"Corso","year":"2007","journal-title":"Leukemia"},{"issue":"10","key":"10.4065\/83.9.1032_bib114","doi-asserted-by":"crossref","first-page":"1479","DOI":"10.1359\/jbmr.0707onj","article-title":"Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research [editorial]","volume":"22","author":"Khosla","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"11","key":"10.4065\/83.9.1032_bib115","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"issue":"34","key":"10.4065\/83.9.1032_bib116","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.4065\/83.9.1032_bib117","doi-asserted-by":"crossref","first-page":"3951","DOI":"10.1182\/blood-2006-07-033571","article-title":"Osteonecrosis of the jaws in newly diagnosed multiple myeloma patients treated with zoledronic acid and thalidomide-dexamethasone [letter]","volume":"108","author":"Tosi","year":"2006","journal-title":"Blood"},{"issue":"22","key":"10.4065\/83.9.1032_bib118","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw\u2014do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.4065\/83.9.1032_bib119","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1016\/S0278-2391(03)00720-1","article-title":"Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic [letter]","volume":"61","author":"Marx","year":"2003","journal-title":"J Oral Maxillofac Surg"},{"issue":"18","key":"10.4065\/83.9.1032_bib120","doi-asserted-by":"crossref","first-page":"1895","DOI":"10.1056\/NEJMc076132","article-title":"Alendronate and atrial fibrillation [letter]","volume":"356","author":"Cummings","year":"2007","journal-title":"N Engl J Med"},{"issue":"8","key":"10.4065\/83.9.1032_bib121","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1001\/archinte.168.8.826","article-title":"Use of alendronate and risk of incident atrial fibrillation in women","volume":"168","author":"Heckbert","year":"2008","journal-title":"Arch Intern Med"},{"issue":"7648","key":"10.4065\/83.9.1032_bib122","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1136\/bmj.39507.551644.BE","article-title":"Use of bisphosphonates among women and risk of atrial fibrillation and flutter: population based case-control study","volume":"336","author":"Sorensen","year":"2008","journal-title":"BMJ"},{"issue":"7","key":"10.4065\/83.9.1032_bib123","first-page":"712","article-title":"Yearly zoledronic acid in postmenopausal osteoporosis [letter]","volume":"357","author":"Karam","year":"2007","journal-title":"N Engl J Med"},{"issue":"6","key":"10.4065\/83.9.1032_bib124","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1016\/j.bone.2003.08.004","article-title":"Tissue mineralization is increased following 1-year treatment with high doses of bisphosphonates in dogs","volume":"33","author":"Burr","year":"2003","journal-title":"Bone"},{"issue":"10","key":"10.4065\/83.9.1032_bib125","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.1359\/jbmr.070609","article-title":"Microcrack frequency and bone remodeling in postmenopausal osteoporotic women on long-term bisphosphonates: a bone biopsy study","volume":"22","author":"Chapurlat","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"3","key":"10.4065\/83.9.1032_bib126","doi-asserted-by":"crossref","first-page":"1294","DOI":"10.1210\/jc.2004-0952","article-title":"Severely suppressed bone turnover: a potential complication of alendronate therapy","volume":"90","author":"Odvina","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"issue":"19","key":"10.4065\/83.9.1032_bib127","doi-asserted-by":"crossref","first-page":"2048","DOI":"10.1056\/NEJMc062268","article-title":"Suppressed bone turnover during alendronate therapy for high-turnover osteoporosis [letter]","volume":"355","author":"Armamento-Villareal","year":"2006","journal-title":"N Engl J Med"},{"issue":"4","key":"10.4065\/83.9.1032_bib128","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1016\/j.bone.2006.04.032","article-title":"Severe hypocalcemia following bisphosphonate treatment in a patient with Paget's disease of bone","volume":"39","author":"Whitson","year":"2006","journal-title":"Bone"},{"issue":"2","key":"10.4065\/83.9.1032_bib129","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1046\/j.1365-2141.2002.03835_4.x","article-title":"Severe increase in creatinine with hypocalcaemia in thalidomide-treated myeloma patients receiving zoledronic acid infusions [letter]","volume":"119","author":"Jones","year":"2002","journal-title":"Br J Haematol"},{"issue":"2","key":"10.4065\/83.9.1032_bib130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1385\/ENDO:14:2:159","article-title":"Prolonged, symptomatic hypocalcemia with pamidronate administration and subclinical hypoparathyroidism","volume":"14","author":"Mishra","year":"2001","journal-title":"Endocrine"},{"issue":"1","key":"10.4065\/83.9.1032_bib131","doi-asserted-by":"crossref","first-page":"48","DOI":"10.4158\/EP.12.1.48","article-title":"Bisphosphonate-induced hypocalcemia: report of 3 cases and review of literature","volume":"12","author":"Maalouf","year":"2006","journal-title":"Endocr Pract"},{"issue":"1","key":"10.4065\/83.9.1032_bib132","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1111\/j.1365-2249.2005.02665.x","article-title":"The bisphosphonate acute phase response: rapid and copious production of proinflammatory cytokines by peripheral blood gd T cells in response to aminobisphosphonates is inhibited by statins","volume":"139","author":"Hewitt","year":"2005","journal-title":"Clin Exp Immunol"},{"issue":"12","key":"10.4065\/83.9.1032_bib133","doi-asserted-by":"crossref","first-page":"1989","DOI":"10.1007\/s00198-005-1986-1","article-title":"Prescription-event monitoring study on 13,164 patients prescribed risedronate in primary care in England","volume":"16","author":"Barrera","year":"2005","journal-title":"Osteoporos Int"},{"key":"10.4065\/83.9.1032_bib134","author":"US Food and Drug Administration"},{"issue":"3","key":"10.4065\/83.9.1032_bib135","first-page":"346","article-title":"Alendronate and risedronate: reports of severe bone, joint, and muscle pain [letter]","volume":"165","author":"Wysowski","year":"2005","journal-title":"Arch Intern Med"},{"issue":"1","key":"10.4065\/83.9.1032_bib136","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5414\/CNP61063","article-title":"Pamidronate-induced nephrotoxic tubular necrosis\u2014a case report","volume":"61","author":"Smetana","year":"2004","journal-title":"Clin Nephrol"},{"issue":"17","key":"10.4065\/83.9.1032_bib137","doi-asserted-by":"crossref","first-page":"1676","DOI":"10.1056\/NEJM200310233491721","article-title":"Renal failure with the use of zoledronic acid [letter]","volume":"349","author":"Chang","year":"2003","journal-title":"N Engl J Med"},{"issue":"5","key":"10.4065\/83.9.1032_bib138","doi-asserted-by":"crossref","first-page":"752","DOI":"10.1111\/j.1532-5415.2007.01161.x","article-title":"Secondary hyperparathyroidism due to hypovitaminosis D affects bone mineral density response to alendronate in elderly women with osteoporosis: a randomized controlled trial","volume":"55","author":"Barone","year":"2007","journal-title":"J Am Geriatr Soc"},{"issue":"3","key":"10.4065\/83.9.1032_bib139","doi-asserted-by":"crossref","first-page":"266","DOI":"10.1056\/NEJMra070553","article-title":"Vitamin D deficiency","volume":"357","author":"Holick","year":"2007","journal-title":"N Engl J Med"},{"issue":"4","key":"10.4065\/83.9.1032_bib140","first-page":"1","article-title":"Optimal calcium intake","volume":"12","author":"National Institutes of Health","year":"1994","journal-title":"NIH Consens Statement"},{"key":"10.4065\/83.9.1032_bib142","unstructured":"Dietary Reference Intakes (DRIs): Summary Tables; 2004."}],"container-title":["Mayo Clinic Proceedings"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611606071?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0025619611606071?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,7]],"date-time":"2025-02-07T00:59:09Z","timestamp":1738889949000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0025619611606071"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,9]]},"references-count":141,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2008,9]]}},"alternative-id":["S0025619611606071"],"URL":"https:\/\/doi.org\/10.4065\/83.9.1032","relation":{},"ISSN":["0025-6196"],"issn-type":[{"value":"0025-6196","type":"print"}],"subject":[],"published":{"date-parts":[[2008,9]]}}}